Abstract |
Seventy seven patients affected by postphlebitic syndrome (PPS) during acute inflammatory and/or obstructive complications were controlled. Thirty nine patients were treated with a new low molecular weight heparin ( Fluxum), 16,000 I.U. AXa/day subcutaneously for 10 days and, subsequently, 8,000 I.U. AXa/day subcutaneously for up to 50 days. Thirty eight patients were treated with 20,000 I.U./day i.v. for 10 days of sodium heparin and, subsequently, with 12,500 I.U./day of calcium heparin by subcutaneous injection for up to 50 days. Clinical symptoms ( pain, oedema, hyperemia, rashes, itching, dermatitis, ulceration) and instrumental patterns (Doppler) were recorded. Fluxum had an evident effect on the improvement of patient's clinical performance during acute complications of PPS.
|
Authors | S Verardi, A Ippoliti, G R Pistolese |
Journal | International angiology : a journal of the International Union of Angiology
(Int Angiol)
1988 Jul-Sep
Vol. 7
Issue 3 Suppl
Pg. 33-40
ISSN: 0392-9590 [Print] Italy |
PMID | 2850325
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Heparin, Low-Molecular-Weight
- calcium heparin
- Heparin
|
Topics |
- Aged
- Female
- Heparin
(therapeutic use)
- Heparin, Low-Molecular-Weight
(therapeutic use)
- Humans
- Male
- Middle Aged
- Phlebitis
(drug therapy, etiology)
- Postphlebitic Syndrome
(complications)
- Thrombophlebitis
(drug therapy, etiology)
|